- Home
- BBT vs ADPT Comparison
BBT vs ADPT Comparison
Compare BBT & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BBT | ADPT |
|---|---|---|
| Founded | 1846 | 2009 |
| Country | United States | United States |
| Employees | 2050 | N/A |
| Industry | Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.0B |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | BBT | ADPT |
|---|---|---|
| Price | $29.32 | $12.76 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 9 |
| Target Price | ★ $33.25 | $17.78 |
| AVG Volume (30 Days) | 701.1K | ★ 2.2M |
| Earning Date | 05-08-2026 | 04-30-2026 |
| Dividend Yield | ★ 4.41% | N/A |
| EPS Growth | N/A | ★ 63.89 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $276,976,000.00 |
| Revenue This Year | $77.88 | $3.98 |
| Revenue Next Year | $4.31 | $22.72 |
| P/E Ratio | $29.98 | ★ N/A |
| Revenue Growth | N/A | ★ 54.77 |
| 52 Week Low | $22.81 | $6.68 |
| 52 Week High | $32.00 | $20.76 |
Technical Indicators
Market Signals| Indicator | BBT | ADPT |
|---|---|---|
| Relative Strength Index (RSI) | 48.98 | 35.49 |
| Support Level | $29.17 | $12.24 |
| Resistance Level | $29.63 | $13.45 |
| Average True Range (ATR) | 0.72 | 0.75 |
| MACD | 0.05 | -0.00 |
| Stochastic Oscillator | 56.22 | 30.88 |
Price Performance
Historical ComparisonAbout BBT Beacon Financial Corporation
Beacon Financial Corp operates as a multi-bank holding company. It offers commercial, business, and retail banking services, including a full complement of cash management products, online banking services, and consumer and residential loans.
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.